Q3 2025 Medexus Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Medexus Pharmaceuticals Inc (MEDXF) successfully completed the FDA review process for GRAFAPEX, which holds Orphan Drug Designation, granting at least seven years of regulatory exclusivity.
- The company reported a strong fiscal Q3 2025 with revenue of $30 million, an increase from $25.2 million in the same period last year.
- Adjusted EBITDA for fiscal Q3 2025 was $5.8 million, up from $3.2 million in the same period last year, reflecting effective financial discipline.
- Medexus completed a CAD30 million public offering, strengthening its balance sheet and providing financial flexibility.
- The company is preparing for the commercial launch of GRAFAPEX in the United States, with expectations of significant revenue growth potential.
- Medexus owes a $15 million regulatory milestone payment to its partner Medac, which could impact cash flow.
- The company received a notice of deficiency from Health Canada regarding its new drug submission for terbinafine hydrochloride, indicating potential delays or challenges.
- IXINITY unit demand in the United States decreased by 1% over the trailing 12-month period, and future demand is expected to remain stable rather than grow.
- Rupall's market exclusivity in Canada expired, leading to anticipated generic competition and potential revenue impact.
- The performance of Gleolan in the United States has been underwhelming, with only single-digit growth, leading to uncertainty about continued investment in the product.
Good morning, everyone. Welcome to the Medexus Pharmaceuticals third quarter, 2025 conference call.
(Operator Instructions) Please note this conference is being recorded. I will now turn the conference over to your host, Victoria Rutherford Investor Relations of Medexus over to you.
Thank you and good morning, everyone Welcome to the Medexus Pharmaceuticals third quarter, 2025 earnings call on the call this morning are Ken d'Entremont, Chief Executive Officer and Brendon Buschman, Chief Financial Officer. If you have any questions after the conference call or would like further information about the company, please contact Adelaide Capital at 480-625-5772.
I would like to remind everyone that this discussion will include forward-looking information as defined in securities laws. Actual results may differ materially from historical results or results anticipated by the forward-looking information.
In addition, this discussion will also include non-GAAP measures
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
